ACON vs XTNT vs GKOS

For growth investors, Aclarion, Inc.

(ACON) is the stronger pick with 999999% revenue growth year-over-year, versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -100. 0% for Aclarion, Inc. (ACON). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus ACON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.

(XTNT) is the lower-risk stock at 0. 67β versus Glaukos Corporation's 1. 16β — meaning GKOS is approximately 73% more volatile than XTNT relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 82% for Xtant Medical Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aclarion, Inc.

(ACON) is pulling ahead at 999999% versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). On earnings-per-share growth, the picture is similar: Aclarion, Inc. grew EPS 99. 8% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, ACON leads at 106. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Xtant Medical Holdings, Inc.

(XTNT) is the more profitable company, earning -14. 0% net margin versus -95. 5% for Aclarion, Inc. — meaning it keeps -14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XTNT leads at -10. 3% versus -93. 1% for ACON. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ACON (100.

0% yield) pays a dividend. XTNT, GKOS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Aclarion, Inc.

(ACON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), 100. 0% yield). Both have compounded well over 10 years (ACON: -100. 0%, GKOS: +454. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

ACON pays a dividend while XTNT, GKOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.